Arteriosclerosis and Thrombosis, Vol 14, 679-685, Copyright © 1994 by American Heart Association
ARTICLES |
M Guerin, PJ Dolphin and MJ Chapman
Institut National de la Sante et de la Recherche Medicale, Hopital de la Pitie, Paris, France.
Elevated cholesteryl ester transfer protein-mediated transfer of cholesteryl ester (CE) from high-density lipoprotein (HDL) to low- density lipoprotein (LDL) may contribute to the atherogenicity of LDL in subjects with familial hypercholesterolemia (FH). To identify the major CE acceptors among LDL subspecies, we investigated the qualitative and quantitative features of CE transfer and exchange to LDL on incubation of plasma under physiological conditions. LDL subspecies were fractionated by density-gradient ultra-centrifugation. Both mass transfer and exchange of HDL CE to and with very-low-density lipoprotein plus intermediate-density lipoprotein and LDL were linear for the first 6 hours of incubation. Thereafter mass transfer ceased, but exchange continued at a comparable rate. The rate of CE mass transfer to apolipoprotein B-containing lipoproteins was significantly enhanced in heterozygous FH subjects compared with normolipidemic individuals (91.6 +/- 28.2 versus 52.9 +/- 19.6 micrograms CE/h per milliliter plasma, FH versus normal subjects, P < .02). In FH subjects the predominant LDL subspecies (LDL 3 and 4, d = 1.029 to 1.050 g/mL) accounted for 59.7 +/- 9.2% of the total CE transferred to LDL from HDL. By contrast, expression of CE mass transfer relative to the mass of each lipoprotein acceptor showed the triglyceride (TG)-rich (10.7% to 17.3%), light LDL subspecies (LDL 1 and 2, d = 1.019 to 1.029 g/mL) to represent the preferential CE acceptors (LDL 1 and 2, 94.8 to 136.5 micrograms CE/mg LDL mass; LDL 3 through 5 [d = 1.029 to 1.063 g/mL], 47.1 to 64.1 micrograms CE/mg LDL mass).(ABSTRACT TRUNCATED AT 250 WORDS)
This article has been cited by other articles:
![]() |
L. K. Potter, D. L. Sprecher, M. C. Walker, and F. L. Tobin Mechanism of inhibition defines CETP activity: a mathematical model for CETP in vitro J. Lipid Res., November 1, 2009; 50(11): 2222 - 2234. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. W.A. van der Hoorn, W. de Haan, J. F.P. Berbee, L. M. Havekes, J. W. Jukema, P. C.N. Rensen, and H. M.G. Princen Niacin Increases HDL by Reducing Hepatic Expression and Plasma Levels of Cholesteryl Ester Transfer Protein in APOE*3Leiden.CETP Mice Arterioscler Thromb Vasc Biol, November 1, 2008; 28(11): 2016 - 2022. [Abstract] [Full Text] [PDF] |
||||
![]() |
B.-H. Chung, P. Liang, S. Doran, B. H. S. Cho, and F. Franklin Postprandial chylomicrons: potent vehicles for transporting cholesterol from endogenous LDL+HDL and cell membranes to the liver via LCAT and CETP J. Lipid Res., July 1, 2004; 45(7): 1242 - 1255. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Le Goff, M. Guerin, L. Petit, M. J. Chapman, and J. Thillet Regulation of human CETP gene expression: role of SP1 and SP3 transcription factors at promoter sites -690, -629, and -37 J. Lipid Res., July 1, 2003; 44(7): 1322 - 1331. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Chancharme, P. Therond, F. Nigon, S. Zarev, A. Mallet, E. Bruckert, and M. J. Chapman LDL particle subclasses in hypercholesterolemia: molecular determinants of reduced lipid hydroperoxide stability J. Lipid Res., March 1, 2002; 43(3): 453 - 462. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. J. Talmud, K. L. Edwards, C. M. Turner, B. Newman, J. M. Palmen, S. E. Humphries, and M. A. Austin Linkage of the Cholesteryl Ester Transfer Protein (CETP) Gene to LDL Particle Size : Use of a Novel Tetranucleotide Repeat Within the CETP Promoter Circulation, May 30, 2000; 101(21): 2461 - 2466. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. J. Packard, T. Demant, J. P. Stewart, D. Bedford, M. J. Caslake, G. Schwertfeger, A. Bedynek, J. Shepherd, and D. Seidel Apolipoprotein B metabolism and the distribution of VLDL and LDL subfractions J. Lipid Res., February 1, 2000; 41(2): 305 - 318. [Abstract] [Full Text] |
||||
![]() |
R. Frénais, K. Ouguerram, C. Maugeais, J. S. Marchini, P. Benlian, J. M. Bard, T. Magot, and M. Krempf Apolipoprotein A-I kinetics in heterozygous familial hypercholesterolemia: a stable isotope study J. Lipid Res., August 1, 1999; 40(8): 1506 - 1511. [Abstract] [Full Text] |
||||
![]() |
T. S. Lassel, M. Guerin, S. Auboiron, M. J. Chapman, and B. Guy-Grand Preferential Cholesteryl Ester Acceptors Among Triglyceride-Rich Lipoproteins During Alimentary Lipemia in Normolipidemic Subjects Arterioscler Thromb Vasc Biol, January 1, 1998; 18(1): 65 - 74. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. J. Packard and J. Shepherd Lipoprotein Heterogeneity and Apolipoprotein B Metabolism Arterioscler Thromb Vasc Biol, December 1, 1997; 17(12): 3542 - 3556. [Abstract] [Full Text] |
||||
![]() |
M. Guerin, E. Bruckert, P. J. Dolphin, G. Turpin, and M. J. Chapman Fenofibrate Reduces Plasma Cholesteryl Ester Transfer From HDL to VLDL and Normalizes the Atherogenic, Dense LDL Profile in Combined Hyperlipidemia Arterioscler Thromb Vasc Biol, June 1, 1996; 16(6): 763 - 772. [Abstract] [Full Text] |
||||
![]() |
T. Murakami, S. Michelagnoli, R. Longhi, G. Gianfranceschi, F. Pazzucconi, L. Calabresi, C. R. Sirtori, and G. Franceschini Triglycerides Are Major Determinants of Cholesterol Esterification/Transfer and HDL Remodeling in Human Plasma Arterioscler Thromb Vasc Biol, November 1, 1995; 15(11): 1819 - 1828. [Abstract] [Full Text] |
||||
![]() |
M. Guerin, P. J. Dolphin, C. Talussot, J. Gardette, F. Berthezene, and M. J. Chapman Pravastatin Modulates Cholesteryl Ester Transfer From HDL to ApoB-Containing Lipoproteins and Lipoprotein Subspecies Profile in Familial Hypercholesterolemia Arterioscler Thromb Vasc Biol, September 1, 1995; 15(9): 1359 - 1368. [Abstract] [Full Text] |
||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1994 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |